Datapoint: Libtayo Scores Second Skin Cancer Nod

The FDA last week approved Regeneron Pharmaceuticals, Inc. and Sanofi’s Libtayo for the treatment of advanced basal cell carcinoma (BCC) that has not responded to previous treatment in some patients. The anti-PD-1 inhibitor is the first immunotherapy drug approved to treat BCC. Libtayo was approved for the treatment of metastatic cutaneous squamous cell carcinoma in September 2018, and currently holds preferred placement under the pharmacy benefit for 9% of all covered lives. Libtayo is not covered for 21% of lives.

SOURCE: MMIT Analytics, as of 2/11/21

0 Comments
© 2024 MMIT
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 23

Datapoint: Centene Pledges Nearly $1B for Affordable Housing

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 22

Datapoint: CMS Extends Medicaid Redetermination Deadline

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
May 21

Datapoint: Aetna Shut Out of Medicaid Contract Awards

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today